Citations

Clear

6729 citation(s) found for "Li, Mark".

Anatomic subsets of cholangiocarcinoma: More different than alike
Dong, Yawen , Stumpf, Hannah E. , Smoot, Rory L., Starlinger, Patrick P., Yarchoan, Mark , Gores, Gregory J., Ilyas, Sumera, Gores, Gregory J. , Ilyas, Sumera I. , Starlinger, Patrick , Gores, Gregory J. , Starlinger, Patrick , Yarchoan, Mark , Ilyas, Sumera Irie , Dong, Yawen , Smoot, Rory L.

Mayo Clinic

Hepatology | January 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001672 | PMID 41525598 Get It

Cholangiocarcinoma (CCA) represents a biologically and clinically heterogeneous group of biliary tract malignancies. Growing evidence underscores that the 3 major anatomic subtypes—intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA)—are distinct tumor entities rather than a single disease. Each subtype differs in embryologic origin, carcinogenesis mechanisms, molecular landscape, and immunogenic profile, all of which contribute to variability in diagnosis, treatment responsiveness, and prognosis. The importance of understanding these distinctions is reinforced by the rising global incidence of CCA, which highlights the need for precision medicine approaches based on these subtypes. Recent advances have deepened our insight into subtype-specific risk factors, including chronic biliary diseases and metabolic conditions, while artificial intelligence–driven tools are improving diagnostic accuracy and risk stratification. Surgical innovations now allow for more tailored resections and perioperative care, and therapeutic strategies are increasingly guided by molecular and immune profiling. Emerging strategies for early diagnosis and chemoprevention in high-risk populations further emphasize the significance of recognizing the unique biology of each subtype. In this review, we provide a comprehensive overview of the distinct anatomic subsets of CCA, integrating their molecular and biological foundations with clinical management to inform practice and guide future research.
Mechanical Dyssynchrony and Perfusion Heterogeneity Predict Adverse LV Remodeling in Patients with and without LBBB
Brandao, Simone Cristina Soares, Joseph, Lee , Brown, Jenifer M. , Lopez, Diana M. , Ramirez, Giselle Chiprez, Kavanagh, P A U L, Kriekinge, Serge D. Van , Liang, Joanna X., Builoff, Valerie , Divakaran, Sanjay, Weber, Brittany, Hainer, Jon, Carre, Sylvain , Blankstein, Ron, Dorbala, Sharmila, Le, Viet T., Mason, Steve, Chareonthaitawee, Panithaya, Wopperer, Samuel, Rosamond, Thomas, Berman, Daniel S., Dey, Damini, Carli, Marcelo F. Di, Slomka, Piotr J, Huck, Daniel, Soares Brandão, Simone Cristina , Divakaran, Sanjay , Slomka, Piotr J , Brown, Jenifer Michelle , Lopez, Diana, Lemley, Mark , Kavanagh, Paul , Weber, Brittany , Hainer, Jon , Blankstein, Ron , Dorbala, Sharmila , Le, Viet T. , Mason, Steve, Knight, Stacey , Chareonthaitawee, Panithaya , Wopperer, Samuel, Berman, Daniel S. , Dey, Damini , Carli, Marcelo F. Di , Huck, Daniel

Mayo Clinic

No container title available | January 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.09.26343726 | PMID 41646827 Get It

Abstract Aims Left bundle branch block (LBBB) is associated with mechanical dyssynchrony, heterogeneous perfusion, and adverse left ventricular (LV) remodeling. However, not all patients with LBBB develop cardiomyopathy, and dyssynchrony can occur without conduction defects. The role of microvascular dysfunction remains uncertain. We aimed to assess how mechanical dyssynchrony and perfusion heterogeneity relate to LV remodeling and function in patients with and without LBBB. Methods and results We retrospectively analyzed 233 patients with isolated LBBB and 932 matched controls who underwent PET myocardial perfusion imaging, assessing mechanical dyssynchrony (phase entropy), myocardial blood flow (MBF), coronary vascular resistance (CVR), myocardial flow reserve (MFR), septal-to-lateral MBF ratio (SLR) for perfusion heterogeneity, LV volumes, and ejection fraction (EF). Compared to controls, patients with LBBB had greater dyssynchrony (56% vs. 40%), larger LV volumes, and lower EF (54% vs. 67%) (all p <0.001), and had higher stress CVR (37 vs. 34 mmHg/mL·min⁻¹·g⁻¹), lower stress MBF (2.4 vs. 2.6 mL/min/g), reduced MFR (2.4 vs. 2.6), and lower SLR (0.95 vs. 1.00) (all p <0.05). Among patients with dyssynchrony, SLR<1.0 identified those with more adverse remodeling. In multivariable regression, phase entropy and SLR independently predicted LV volumes and EF, with adverse effects of SLR reduction amplified in LBBB (interaction p <0.01). In the Cox proportional hazards analysis, phase entropy (HR:1.02, p =0.01), MFR (HR:0.62, p <0.001), and LVEF (HR:0.97, p <0.001) were independently associated with mortality and heart failure hospitalization, whereas LBBB was not. Conclusions Mechanical dyssynchrony and perfusion heterogeneity independently predict adverse LV remodeling, irrespective of LBBB. Integrated imaging enhances cardiomyopathy stratification.
Mutational analysis and identification of potential biomarkers in patients with metastatic pancreatic cancer treated with the combination of the GSK-3 inhibitor elraglusib and gemcitabine/nab-paclitaxel in the 1801 Part 3B phase 2 study.
Shroff, Rachna T. , Carneiro, Benedito A. , Cervantes, Andres, Sahai, Vaibhav , Ploquin, Anne , Hiret, Sandrine , Lopez, Charles D., Pernot, S., Kaván, Petr, Mulcahy, Mary Frances, Smith, Sheri , Jaros, Mark, Bekaii-Saab, Tanios S., Mazar, Andrew P. , Sahai, Vaibhav , Ugolkov, Andrey , Mahalingam, Devalingam , Coveler, Andrew L. , Cervantes, Andrés , LoConte, Noelle K. , Lopez, Charles D. , Pernot, Simon , Mulcahy, Mary F. , Carr, Ryan M , Giles, Francis Joseph , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 761-761

10.1200/jco.2026.44.2_suppl.761 Get It

761 Background: Glycogen Synthase Kinase-3β (GSK-3β) is a known therapeutic target in cancer including pancreatic adenocarcinoma (PDAC). The combination of elraglusib (9-ING-41), a novel GSK-3 inhibitor, and gemcitabine/nab-paclitaxel (GnP) is being evaluated as first-line therapy for patients with metastatic PDAC (mPDAC). We previously reported topline results indicating that the 1801 Part 3B phase 2 trial (NCT03678883) met its primary endpoint, showing a clinically meaningful survival benefit in patients treated with elraglusib/GnP compared to GnP alone. Here, we examined whether gene mutations correlated with clinical outcomes in mPDAC patients enrolled in this randomized phase 2 trial. Methods: For mutational analysis, archival tumor and/or plasma samples were obtained from 53 (GnP group) and 117 (elraglusib/GnP group) patients with previously untreated mPDAC. Cell-free DNA and/or tumor-extracted DNA were analyzed using the next generation sequencing. The comparison of the response rates was performed with the use of Chi-square tests. Kaplan-Meier survival curves were compared by log-rank (Mantel-Cox) tests. Results: Mutational analysis identified frequently mutated genes (detectable in ≥25% of patients): KRAS (141/170, 83%), TP53 (121/170, 71%), and CDKN2A (56/170, 33%). Mutations in KRAS, TP53, or CDKN2A genes did not correlate with objective response rate. Based on 81% of the recorded death events in the elraglusib/GnP group and 91% in the GnP group (topline data April, 2025), KRAS and TP53 gene mutations were associated with worse overall survival (OS) in patients treated with elraglusib/GnP (p<0.05) but not in GnP-treated patients. The rate of triple (KRAS+TP53+CDKN2A) mutations was significantly higher in the patients with OS<2 months as compared to the patients with OS>2 months in the elraglusib/GnP group (p<0.05) but not in the GnP group. Conclusions: Our preliminary results identified KRAS and TP53 gene mutations as potential predictive biomarkers of clinical outcome in elraglusib/GnP-treated mPDAC patients. Updated OS data and mutational analysis will be included in the final presentation. Clinical trial information: NCT03678883 .
Results from the randomized phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
Shroff, Rachna T. , Carneiro, Benedito A. , Ji, Yan, Cervantes, Andres, Sahai, Vaibhav , Ploquin, Anne , Hiret, Sandrine , Percent, Ivor John, Lopez, Charles D., Pernot, S., Kaván, Petr, Mulcahy, Mary Frances, Mazar, Andrew P. , Jaros, Mark, Bekaii-Saab, Tanios S., Sahai, Vaibhav , Mahalingam, Devalingam , Coveler, Andrew L. , Cervantes, Andrés , LoConte, Noelle K. , Percent, Ivor , Lopez, Charles D. , Pernot, Simon , Mulcahy, Mary F. , Carr, Ryan M , Giles, Francis Joseph , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 653-653

10.1200/jco.2026.44.2_suppl.653 Get It

653 Background: Elraglusib (9-ING-41), a novel small molecule inhibitor of GSK-3ß, has a multimodal mechanism of action that enhances chemotherapy cytotoxicity and regulates anti-tumor immune cell response. Elraglusib was evaluated in a randomized, open-label, phase 2 study (NCT03678883) comparing elraglusib/GnP vs GnP in previously untreated mPDAC. Methods: Pts were randomized 2:1 to GnP plus elraglusib 9.3 mg/kg IV once weekly or GnP. Primary endpoint was mOS, with 1-yr OS rate estimates summarizing clinical benefit throughout the study. Secondary endpoints were ORR, mPFS, and TEAEs/TRAEs. Pre-dose cytokines, mutational analysis, and immunophenotyping were correlated with outcomes. An oral presentation at ASCO 2025 discussed preliminary data. Results: As of 27 April 2025, the primary analysis set included 155 pts in the elraglusib/GnP arm and 78 pts in the GnP arm, with 52.8% males and 57.5% ECOG PS 1. The 1-yr OS rate was 44.1% with elraglusib/GnP vs 22.3% with GnP; the mOS was 10.1 mo with elraglusib/GnP vs 7.2 mo with GnP (HR, 0.62; p=0.01) with approximately 79% events recorded (25.8% of pts on elraglusib/GnP and 10.3% on GnP were censored with the majority at >12 mo OS). Improved OS with elraglusib/GnP was consistent across all randomized pts and subgroups regardless of liver metastases, ECOG status, or baseline CA 19-9 levels. Most common TRAE with elraglusib/GnP was grade 1-2 transient visual impairment (66.5% pts vs 0 with GnP). Most common grade ≥3 TEAEs with elraglusib/GnP (vs GnP) were neutropenia 52.3% (vs 30.8%) and anemia 25.2% (vs 29.5%). No differences in sepsis/febrile neutropenia rates were between arms. RAS , TP53 and CDKN2A co-mutations were associated with worse OS in the elraglusib/GnP arm only (p<0.05). Elevation in pre-dose cytokines including CXCL2 correlated with improved OS in the elraglusib/GnP arm. Additionally, increased CD8+ T cells, granzyme B, and NK cells and reduced MDSCs were observed in elraglusib-treated tumors. Conclusions: A significant benefit for 1-yr OS and mOS and a favorable trend for ORR were observed with the addition of elraglusib to GnP. The mOS was lower in the GnP arm vs historical studies, likely due to early deaths in the first 2 months, but aligns with mOS estimates in the real-world analysis with broad heterogeneous population. Our study included 19.7% pts with albumin <3.0 g/dL and >25% with CA 19.9 levels > 8,000 U/mL. Immune correlates support elraglusib’s immune-modulatory role. Final efficacy data cut-off in Dec 2025 and correlative studies will be presented. Clinical trial information: NCT03678883 . Outcome Elraglusib/GnPN=155 GnPN=78 Primary endpoint: mOS (mo)HR=0.62; log-rank p=0.01 10.1 7.2 Events, n (%) 115 (74.2) 70 (89.7) Primary endpoint: 1-yr OS (%) 44.1 22.3 18-month OS (%) 20.5 4.4 24-month OS (%) 13.2 0 mPFS (mo)HR=0.9; p=NS 5.6 5.1 Events, n (%) 136 (87.7) 75 (96.2) ORR, n (%) 44 (28.4) 17 (21.8)
Use of PPV of [ 18 F]FAPI-74 PET to identify FAP expression in gastrointestinal cancers: Results from a prospective multicenter phase 2 study.
Kulkarni, Harshad R., Rini, Josephine N. , Girgis, Mark, Calais, Jérémie, Jayaprakasam, Vetri Sudar , Goenka, Ajit H. , Adams, Bridget, Zeller, Alyse, Razmaria, Ali Aria , Calais, Jérémie , Calais, Jeremie , Esfahani, Shadi A. , Mosessian, Sherly , Kulkarni, Harshad R.

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 292-292

10.1200/jco.2026.44.2_suppl.292 Get It

292 Background: Fibroblast activation protein (FAP) has high expression in cancer associated fibroblasts (CAFs) in the tumor microenvironment of many solid tumor malignancies. [ 18 F]FAPI-74 is a fluorine-18 labeled FAP-targeting PET imaging tracer with promising characteristics for detection of malignant disease in a variety of cancers. In this multicenter prospective Phase 2 trial, we hypothesized that [ 18 F]FAPI-74 PET would have a high positive predictive value (PPV) for detecting FAP-expressing tumor tissue in a variety of gastrointestinal (GI) malignancies. Methods: This Phase 2 multicenter trial was conducted in the United States at MGH, MSKCC, BAMF, Northwell, UCLA and Mayo (NCT05641896). Eligible GI cancers in the study included hepatocellular carcinoma, cholangiocarcinoma, gastric, esophageal, pancreatic, and colorectal cancer. Each subject underwent one [ 18 F]FAPI-74 PET scan, and a tissue sample was obtained by biopsy and/or surgical resection. The imaging reads were performed centrally by experienced PET readers. The primary objective was to evaluate the PPV of [ 18 F]FAPI-74 PET in detecting FAP-expressing cells from patient collected tissues using centrally evaluated immunohistochemistry (IHC) with positivity defined by the sponsor as an H score higher than 50. The secondary objective was to evaluate the safety profile of [ 18 F]FAPI-74 and its PPV in detecting the presence of GI malignancies using histopathology as the standard of truth. Results: The trial was activated in May 2023, with the last patient imaged in Jan 2025. Of 103 subjects with GI malignancies, the primary site was gastroesophageal in 46 (45%), pancreatic in 22 (21%), colorectal in 17 (17%), hepatobiliary in 10 (10%) and of other GI origin in 8 (8%) cancers. 60 participants were male and 43 female. In total, 60 patients had viable and representative tissue data for efficacy analysis of primary and secondary endpoints. No serious adverse events were reported because of the investigational product. The PPV of [ 18 F]FAPI-74 PET to detect FAP-expressing cells using IHC was 100% (52/52). The sensitivity and specificity for the detection of FAP were 90% (52/58) and 100% (2/2) respectively. The PPVs of [ 18 F]FAPI-74 PET to detect cancer using histopathology as truth standard was 94% (49/52). The sensitivity for the detection of disease was 91% (49/54). Conclusions: The Phase 2 study in GI cancers demonstrates that [ 18 F]FAPI-74 PET detects FAP expression and presence of disease in cancers of the GI tract. PPV of 100% for primary objective and 94% for secondary objective were determined. These results support initiation of a Phase 3 study of [ 18 F]FAPI-74 PET in patients with GI cancers. In addition, [ 18 F]FAPI-74 PET’s reliability in visualizing FAP expression cells in the tumor microenvironment supports a further role in selection of patients for FAP-directed therapies. Clinical trial information: NCT05641896 .
P-1774. Clinical presentation of Cutaneous Leishmaniasis (CL) in returning travelers
Man, Olivia , Enzler, Mark J., Pritt, Bobbi S, Virk, Abinash, Saleh, Omar Abu , Pritt, Bobbi S. , Virk, Abinash

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.1944 Get It

Abstract Background Leishmaniasis is a rare protozoan parasitic disease transmitted through the bite of infected Phlebotomus and Lutzomyia sandflies. Clinical presentation is variable due to numerous species and host immunity differences. We present our clinical experiences with CL to guide timely diagnosis and treatment in returning travelers. Methods We retrospectively analyzed a cohort of adult patients 18+ years old who were diagnosed with CL from 2005 and 2025. We describe the demographic, clinical, and diagnostic features of CL. Results Biopsy-confirmed CL was diagnosed in 20 returning travelers (Table 1) from various endemic regions, most commonly Costa Rica (Fig. 1). The median time from travel to symptom onset was 36.5 days (SD 102), with an additional 75.5 days (SD 87) prior to biopsy diagnosis. All patients were evaluated by dermatology and 70% were evaluated by infectious disease (n=14). On initial presentation, lesions were described as ulcerated (50%, n=10), nodular (30%, n=6), painful (20%, n=4), and necrotic (10%, n=2; Fig. 2). Most lesions were located on the upper extremity (55%, n=11), followed by the face (35%, n=7), lower extremity (30%, n=6), and trunk (15%, n=3). 15% of individuals (n=3) had constitutional symptoms. No patients had definitive mucosal involvement, however, 10% (n=2) endorsed lip edema. No patients had visceral involvement. Species level identification occurred in 14 cases (70%), of which the most common was L.V. panamensis (50%), L.L. mexicana (21%), L. V. guyanensis (14%), L. L. tropica (7%), and L. V. braziliensis (7%). Initial treatments included azoles, liposomal amphotericin B (AmBisome), and miltefosine (each 20%); cryotherapy and parenteral pentamidine (each 10%); with compounded topical paromomycin added in 15% of cases. 35% of individuals (n=7) failed initial treatment and required additional treatment courses due to persistent lesions (57%) or relapse following initial resolution (14%). 10% (n=2) required a third treatment course due to persistent/recurrent lesions. Conclusion While CL in travelers has a variety of clinical manifestations, travel history, knowledge of key clinical features, and lesion patterns can aid in early diagnosis and treatment. CL is associated with early treatment failure rate for uncertain reasons. Disclosures All Authors: No reported disclosures
The Anxious Bipolar Phenotype: Clinical Complexity and Treatment Resistance
Singh, Balwinder, Ho, Ada Man-Choi, Coombes, Brandon, Romo-Nava, Francisco, CUÉLLAR-BARBOZA, Alfredo B., Gardea-Reséndez, Manuel, Bond, David J. , Prieto, Miguel, Pendegraft, Richard, McElroy, Susan, Biernacka, Joanna, Frye, Mark, Bond, David J , Singh, Balwinder , Ho, Ada Man‐Choi , Coombes, Brandon J. , Romo‐Nava, Francisco , Cuéllar‐Barboza, Alfredo B. , Gardea‐Resendez, Manuel , Prieto, Miguel L. , Veldić, Marin , McElroy, Susan L. , Biernacka, Joanna M. , Frye, Mark A.

Mayo Clinic

No container title available | January 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8503080/v1 | PMID 41646373 Get It

Abstract Background Anxiety disorders (ANX) affect 30–60% of individuals with bipolar disorder (BD), yet limited research has systematically examined clinical characteristics and treatment patterns in this comorbid population. This study investigated demographic, clinical, and pharmacotherapeutic differences between individuals with BD with and without comorbid ANX. Methods Cross-sectional data from 2,225 adults with BD enrolled in the Mayo Clinic Bipolar Disorder Biobank were analyzed. Participants were assessed for comorbid ANX, demographics, clinical characteristics, medication use, and treatment response using the Alda-A scale. Results Overall, 61% (n = 1,366) had comorbid ANX. Individuals with BD + ANX were younger (40.4 vs. 43.6 years, p < 0.001), more likely female (66.6% vs. 54.8%, p < 0.001), and exhibited higher rates of rapid cycling (64.2% vs. 45.2%, p < 0.001), suicide attempts (40.4% vs. 24.8%, p < 0.001), substance use disorders (63.5% vs. 54.8%, p < 0.001), and somatic comorbidities (MCIRS: 6.68 vs. 5.42, p < 0.001). Pharmacotherapeutically, BD + ANX individuals were less likely to receive lithium (37.1% vs. 47.8%, p = 0.005) and valproic acid (21.7% vs. 29.6%, p = 0.047), but more likely to receive antidepressants (53.8% vs. 39.5%, p < 0.001), benzodiazepines (39.9% vs. 26.6%, p < 0.001), and gabapentinoids (8.5% vs. 4.5%, p < 0.001). Notably, 17.3% of BD + ANX individuals received antidepressants without mood stabilizer coverage. Treatment response (Alda-A) scores were significantly lower in BD + ANX for lithium (4.91 vs. 6.05, p < 0.001), mood-stabilizing anticonvulsants (5.09 vs. 6.22, p < 0.001), and second-generation antipsychotics (4.67 vs. 5.73, p < 0.001). Similar patterns were observed in both BD-I and BD-II subtypes. Conclusions Individuals with BD + ANX represent a more severely affected subgroup with distinct prescribing patterns favoring antidepressants over mood stabilizers and attenuated mood stabilizers response. These findings highlight the need for anxiety-informed treatment algorithms recognizing anxiety comorbidity as a negative prognostic factor.
Living liver donor safety: Preoperative aspects of living liver donation—Guidelines from the ILTS–iLDLT consensus conference
Patel, Madhukar , Magistri, P., Sayed, Blayne A. , Rammohan, Ashwin, Humar, Abhinav, Abbey, Susan , Badenoch, Heather, Bhangui, Pooja , Cattral, M C, Durand, F., Hibi, Taizo, Jhaveri, Kartik , Kabacam, Gokhan, Khan, Maaz , Malik, Ashish, Nadalin, S., Ng, Vicky L, Petrowsky, Henrik , Pillai, Anjana , TOKAT, YAMAN, Wong, Tiffany, Yilmaz, Sezai, Yoshizumi, T., Nl, Ascher, Broering, Dieter, Burra, Patrizia, Chen, Chao-Long, Lerut, J., Mas, Valeria R. , Taner, Timucin, Terrault, Norah, Vyas, Mary, Wiggins, Chantal, Heimbach, Julie, Ng, Vicky L. , Rela, M., Patel, Madhukar S. , Selzner, Nazia , Sayed, Blayne A , Rammohan, Ashwin , Humar, Abhinav , Abbey, Susan , Ng, Vicky L , Rela, Mohamed , Bhangui, Prashant , Selzner, Nazia , Khan, Mohammad Qasim , Magistri, Paolo , Humar, Abhinav , Cattral, Mark S. , Durand, François , Gross, Jed Adam , Hibi, Taizo , Kabaçam, Gökhan , Malik, Ashish , Nadalin, S., Reddy, Mettu Srinivas , Wong, Tiffany, Yilmaz, Sezai , Yoshizumi, Tomoharu , Bröering, Dieter C. , Burra, Patrizia , Hirschfield, Gideon M. , Taner, Timuçin , Terrault, Norah A. , Heimbach, Julie K. , Rela, Mohamed , Bhangui, Prashant

Mayo Clinic

Liver Transplantation | January 9, 2026 | Volume: 32 | Issue: 7 | Pages: 1049-1065

10.1097/lvt.0000000000000798 | PMID 41511461 Get It

Living donor liver transplantation (LDLT) is an established therapy with curative intent for pediatric and adult patients with acute liver failure and end-stage liver disease. Donor safety remains paramount and commences during preoperative evaluation and assessment. Given the importance of the topic, the International Liver Transplantation Society and International Living Donor Liver Transplantation Group consensus conference on Living Liver Donor Safety was convened in March 2025 (Toronto, Canada). Recommendations were based on the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system for assessment of recommendations, and the Danish model of consensus was followed. This report presents 28 recommendations from the working group focused on addressing clinically relevant questions related to the preoperative aspects of living donor safety including assessment of donor acceptability (age, body mass index and hepatic steatosis; medical conditions and contraindications), medical and surgical workup (liver function and procoagulant workup; anatomical considerations and safe remnant), and psychosocial evaluation (timing and team; underlying conditions; non-directed, paired, and anonymous directed donors; urgent living donor workups for acute liver failure).
Using the Quality Outcomes Database to Identify Minimum Clinically Important Differences for Patients With Cervical Spondylotic Myelopathy
Asher, Anthony L., Lakomkin, Nikita, Mummaneni, Praveen V., Michalopoulos, Giorgos D., Johnson, Sarah E. , Park, Paul J. , Gottfried, Oren N., Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y., Knightly, John J. , Shaffrey, Christopher I., Virk, Michael S. , Fu, Kai-Ming, Tumialán, Luis M. , Turner, Jay D., Uribe, Juan S., Upadhyaya, Cheerag D., Shaffrey, Mark E., Coric, Domagoj , Chou, Dean, Haid, Regis W., Ef, Bisson, Bydon, Mohamad, Katsos, Konstantinos, Asher, Anthony L. , Lakomkin, Nikita , Mummaneni, Praveen V. , Michalopoulos, Giorgos D. , Park, Paul, Asher, Anthony M. , Katsos, Konstantinos, Wang, Michael Y. , Shaffrey, Christopher I. , Fu, Kai-Ming, Turner, Jay D. , Uribe, Juan S. , Chou, Dean , Bisson, Erica F. , Bydon, Mohamad

Mayo Clinic

Neurosurgery | January 9, 2026 | Volume: 98 | Issue: 6 | Pages: 1347-1358

10.1227/neu.0000000000003902 | PMID 41511085 Get It

BACKGROUND AND OBJECTIVES: Minimum clinically important differences (MCIDs) for patient-reported outcome metrics (PROMs) in patients with cervical spondylotic myelopathy (CSM) lack consensus on the most appropriate calculation method. This retrospective study aimed to identify the optimal MCIDs for commonly used PROMs in CSM. METHODS: The CSM database from the Quality Outcomes Database SpineCORe Study Group was analyzed. Baseline, 3-month, and 24-month PROM values for Neck Disability Index (NDI), 5-dimension Euro-quality of life (EQ-5D) in quality-adjusted life years, modified Japanese Orthopaedic Association (mJOA) score, and neck/arm pain numeric rating scale (NRS) were collected. MCIDs were calculated for each PROM using previously validated techniques. MCID values were compared using the area under the curve (AUC) with the North American Spine Society satisfaction scale as an anchor. RESULTS: A total of 1141 patients with CSM undergoing surgery were included in this analysis. Improvement of ≥30% from baseline was the optimal MCID for NDI and neck/arm NRS. At 24 months, the optimal percentage cutoff MCID for these instruments resulted in AUCs of 0.76, 0.72, and 0.67, similar to the 30% improvement method, with AUCs of 0.73, 0.71, and 0.67, respectively. Numeric cutoffs (0.065 at 3 months; 0.149 at 24 months) were the superior MCIDs for EQ-5D. For mJOA score, a severity-adjusted MCID outperformed other methods, yielding an AUC of 0.67 at 24 months. MCIDs were achieved in 63% of patients for NDI, 59% for neck pain NRS, 61% for arm pain NRS, 52% for EQ-5D, and 59% for mJOA score at 24 months. CONCLUSION: Using the Quality Outcomes Database SpineCORe data set, we defined optimal MCIDs for key PROMs in CSM. A ≥30% improvement from baseline was optimal in NDI and arm/neck NRS. An absolute numeric cutoff was superior for EQ-5D (0.149 at the 24-month follow-up). A severity-adjusted MCID performed best for mJOA score. These redefined benchmarks better capture the treatment impact and guide care decisions for patients with CSM.
Imaging Hereditary Cancer Syndromes in the Abdomen and Pelvis
Suman, Garima , Nehra, Avinash , Bohyun, Kim, Nathan, Mark A., Heiken, Jay P. , Kawashima, Akira , Nathan, Mark, Heiken, Jay , Kawashima, Akira

Mayo Clinic

RadioGraphics | January 8, 2026 | Volume: 46 | Issue: 2 | Pages: No page available

10.1148/rg.250106 | PMID 41505282 Get It

Radiologists are uniquely positioned to play a critical role in the detection, surveillance, and characterization of hereditary abdominal cancer syndromes.